keyword
https://read.qxmd.com/read/38544841/patient-reported-outcomes-in-hodgkin-lymphoma-trials-a-systematic-review
#1
Esther Natalie Oliva, Tatyana Ionova, Edward Laane, Mario Csenar, Julia Schroer, Karolin Behringer, Ina Monsef, Annika Oeser, Nicole Skoetz, Sam Salek
BACKGROUND: Lymphoma treatment can lead to long-term consequences such as fatigue, infertility and organ damage. In clinical trials, survival outcomes, clinical response and toxicity are extensively reported while the assessment of treatment on quality of life (QoL) and symptoms is often lacking. OBJECTIVE: We evaluated the use and frequency of patient-reported outcome (PRO) instruments used in randomized controlled trials (RCTs) for Hodgkin lymphoma (HL) and their consistency of reporting...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38532527/management-of-vaccinations-in-patients-with-non-hodgkin-lymphoma
#2
REVIEW
Michele Merli, Andrea Costantini, Silvio Tafuri, Davide Fiore Bavaro, Carla Minoia, Erika Meli, Stefano Luminari, Guido Gini
Vaccinations are fundamental tools in preventing infectious diseases, especially in immunocompromised patients like those affected by non-Hodgkin lymphomas (NHLs). The COVID-19 pandemic made clinicians increasingly aware of the importance of vaccinations in preventing potential life-threatening SARS-CoV-2-related complications in NHL patients. However, several studies have confirmed a significant reduction in vaccine-induced immune responses after anti-CD20 monoclonal antibody treatment, thus underscoring the need for refined immunization strategies in NHL patients...
March 26, 2024: British Journal of Haematology
https://read.qxmd.com/read/38508620/rituximab-combined-anthracycline-free-chemotherapy-in-newly-diagnosed-paediatric-and-adolescent-patients-with-non-high-risk-aggressive-mature-b-cell-lymphoma-protocol-for-a-single-arm-open-label-multicentre-phase-ii-study-the-japan-children-s-cancer-group-multicentre
#3
JOURNAL ARTICLE
Masahiro Sekimizu, Reiji Fukano, Yuhki Koga, Tetsuo Mitsui, Naoto Fujita, Takeshi Mori, Daiki Hori, Makito Tanaka, Kentaro Ohki, Hideto Iwafuchi, Atsuko Nakazawa, Tetsuya Mori, Ryoji Kobayashi, Hiroya Hashimoto, Akiko M Saito, Michi Kamei
INTRODUCTION: Children and adolescents with mature B cell non-Hodgkin lymphoma (B-NHL) are treated with short-intensive chemotherapy. The burden of short-term and long-term toxicity is highly relative to its high cure rate in good-risk patients. Although the addition of rituximab to standard lymphome Malin B (LMB) chemotherapy markedly prolongs event-free survival and overall survival in high-risk patients, the benefit of rituximab in good-risk patients remains to be elucidated. This clinical trial will examine whether the addition of rituximab eliminates anthracyclines in good-risk patients without compromising treatment outcomes...
March 19, 2024: BMJ Open
https://read.qxmd.com/read/38476165/solid-organ-transplantation-and-gut-microbiota-a-review-of-the-potential-immunomodulatory-properties-of-short-chain-fatty-acids-in-graft-maintenance
#4
REVIEW
Manon Jardou, Clarisse Brossier, Pierre Marquet, Nicolas Picard, Anne Druilhe, Roland Lawson
Transplantation is the treatment of choice for several end-stage organ defects: it considerably improves patient survival and quality of life. However, post-transplant recipients may experience episodes of rejection that can favor or ultimately lead to graft loss. Graft maintenance requires a complex and life-long immunosuppressive treatment. Different immunosuppressive drugs ( i.e. , calcineurin inhibitors, glucocorticoids, biological immunosuppressive agents, mammalian target of rapamycin inhibitors, and antiproliferative or antimetabolic agents) are used in combination to mitigate the immune response against the allograft...
2024: Frontiers in Cellular and Infection Microbiology
https://read.qxmd.com/read/38470973/g-csf%C3%A2-%C3%A2-plerixafor-versus-g-csf-alone-mobilized-hematopoietic-stem-cells-in-patients-with-multiple-myeloma-and-lymphoma-a-systematic-review-and-meta-analysis
#5
JOURNAL ARTICLE
Yuyao Li, Xia Qiu, Yupeng Lei, Ruixi Zhou
AIM: The combination of granulocyte-colony stimulating factor (G-CSF) and plerixafor is one of the approaches for hematopoietic stem cell mobilization in patients with multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), and Hodgkin's lymphoma (HL). This systematic review and meta-analysis aimed to determine the ability of G-CSF + plerixafor to mobilize peripheral blood (PB) CD34+ cells and examine its safety profile. METHODS: We performed a database search using the terms 'granulocyte colony stimulating factor', 'G-CSF', 'AMD3100', and 'plerixafor', published up to May 1, 2023...
December 2024: Annals of Medicine
https://read.qxmd.com/read/38464573/rituximab-induced-psoriasis-in-a-patient-with-pemphigus-vulgaris-a-case-report-and-literature-review
#6
Leila Ghadirzade Arani, Shima Moslemi Haghighi, Soheila Nasiri, Sahar Dadkhahfar
KEY CLINICAL MESSAGE: Rituximab which is established as a main treatment for pemphigus vulgaris can be a potential causative factor for development of psoriasis in some patients. It is preferred to avoid using rituximab in patients who had a history of psoriasis. Acquainting medical doctors about rituximab-related cutaneous complications will help them in detection and management. ABSTRACT: Rituximab is a human/murine monoclonal antibody targeting the CD20 antigen on B-lymphocytes surface...
March 2024: Clinical Case Reports
https://read.qxmd.com/read/38464386/recent-preclinical-and-clinical-advances-in-radioimmunotherapy-for-non-hodgkin-s-lymphoma
#7
REVIEW
Hiroki Goto, Yoshioki Shiraishi, Seiji Okada
Radioimmunotherapy (RIT) is a therapy that combines a radioactive nucleotide with a monoclonal antibody (mAb). RIT enhances the therapeutic effect of mAb and reduces toxicity compared with conventional treatment. The purpose of this review is to summarize the current progress of RIT for treating non-Hodgkin's lymphoma (NHL) based on recent preclinical and clinical studies. The efficacy of RIT targeting the B-lymphocyte antigen cluster of differentiation 20 (CD20) has been demonstrated in clinical trials. Two radioimmunoconjugates targeting CD20, yttrium-90 (90 Y)-ibritumomab-tiuxetan (Zevalin) and iodine-131 (131 I)-tositumomab (Bexxar), have been approved in the USA Food and Drug Administration (FDA) for treating relapsed/refractory indolent or transformed NHL in 2002 and 2003, respectively...
2024: Exploration of targeted anti-tumor therapy
https://read.qxmd.com/read/38455716/primary-splenic-diffuse-large-b-cell-lymphoma-a-case-report-and-literature-review-of-a-rare-condition
#8
Mohammed Najdat Seijari, Samer Kaspo, Awni Alshurafa, Amro Elfaieg, Sarah A Elkourashy
INTRODUCTION: Primary splenic lymphoma is a rare lymphoproliferative disorder that involves the spleen, exhibits diverse clinical presentations, and lacks a clear consensus in terms of management strategies. CASE PRESENTATION: We present the case of a 52-year-old patient with a complex medical history marked by multiple chronic medical conditions. The patient was diagnosed with primary splenic lymphoma, specifically the diffuse large B-cell subtype. Treatment for our patient involved a shortened course of chemotherapy (4 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] followed by two doses of rituximab) due to issues related to compliance and treatment-related complications...
2024: Case Reports in Oncology
https://read.qxmd.com/read/38450476/immunobiology-and-treatment-of-cutaneous-t-cell-lymphoma
#9
REVIEW
Rishi R Goel, Alain H Rook
INTRODUCTION: Primary cutaneous T cell lymphomas (CTCL) are a heterogenous group of non-Hodgkin lymphomas derived from skin-homing T cells. These include mycosis fungoides and its leukemic variant Sezary syndrome, as well as the CD30+ lymphoproliferative disorders. AREAS COVERED: In this review, we provide a summary of the current literature on CTCL, with a focus on the immunopathogenesis and treatment of mycosis fungoides and Sezary syndrome. EXPERT OPINION: Recent advances in immunology have provided new insights into the biology of malignant T cells...
March 7, 2024: Expert Review of Clinical Immunology
https://read.qxmd.com/read/38445082/trial-watch-bispecific-antibodies-for-the-treatment-of-relapsed-or-refractory-large-b-cell-lymphoma
#10
REVIEW
Giulio Cassanello, Alejandro Luna de Abia, Lorenzo Falchi
Immunotherapy has shaped the treatment approach to diffuse large B-cell lymphoma (DLBCL), with rituximab leading to remarkable improvements in outcomes for both relapsed and treatment-naïve patients. Recently, groundbreaking immunotherapies like chimeric antigen receptor T-cells have entered the treatment arena for relapsed/refractory (R/R) DLBCL and gained regulatory approval in several countries. The concept of harnessing a patient's own T-cells to combat cancer has been further explored through the development of bispecific antibodies (BsAbs), a class of engineered antibody products designed to simultaneously target two different antigens...
2024: Oncoimmunology
https://read.qxmd.com/read/38421601/twenty-years-of-advancing-discoveries-and-treatment-of-mantle-cell-lymphoma
#11
JOURNAL ARTICLE
Lymphoma Research Foundation Lymphoma Research Foundation
Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma characterized by the t(11;14) chromosomal translocation, which leads to the dysregulation of the cell cycle through overexpression of cyclin D1. Although advances in treatment have improved outcomes, in particular the introduction of Bruton tyrosine kinase inhibitors to the treatment armamentarium and more recently chimeric antigen receptor T-cell therapy, MCL often rapidly develops resistance and has a high rate of relapse. In addition, MCL is clinically heterogeneous...
February 5, 2024: Oncology (Williston Park, NY)
https://read.qxmd.com/read/38415257/plasmablastic-lymphoma-current-knowledge-and-future-directions
#12
REVIEW
Ji-Wei Li, Hong-Ling Peng, Xiao-Yan Zhou, Jing-Jing Wang
Plasmablastic lymphoma (PBL) is an aggressive non-Hodgkin lymphoma associated with HIV infection and immunodeficiency. However, PBL can also be seen immunocompetent individuals in recent studies. PBL was characterized by distinct clinical and pathological features, such as plasmablastic morphology and universal expression of plasma cell markers. The clinicopathologic features were different between HIV-negative and HIV-positive patients. Gene expression analysis identified the unique molecular feature in PBL, including frequent c- MYC rearrangement and downregulation of BCR signaling pathway...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38412928/clinical-outcomes-and-toxicity-in-older-adults-receiving-chimeric-antigen-receptor-t-cell-therapy
#13
JOURNAL ARTICLE
P Connor Johnson, Isabel Neckermann, Hossein Sadrzadeh, Richard Newcomb, Areej R El-Jawahri, Matthew J Frigault
BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape for adults with relapsed/refractory hematologic malignancies, but few studies have examined outcomes in older adults. OBJECTIVE: We aimed to evaluate clinical outcomes and treatment toxicity in older adults receiving CAR-T for hematologic malignancies and describe outcomes and toxicity in older adults age 75+ years compared to those 65-74 years. STUDY DESIGN: We conducted a retrospective analysis of 141 adult patients age 65+ years (46...
February 25, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38398219/innovations-in-antibody-drug-conjugate-adc-in-the-treatment-of-lymphoma
#14
REVIEW
Ali Al Sbihi, Maryam Alasfour, Georgios Pongas
Chemoimmunotherapy and cellular therapy are the mainstay of the treatment of relapsed/refractory (R/R) lymphomas. Development of resistance and commonly encountered toxicities of these treatments limit their role in achieving desired response rates and durable remissions. The Antibody-Drug Conjugate (ADC) is a novel class of targeted therapy that has demonstrated significant efficacy in treating various cancers, including lymphomas. To date, three ADC agents have been approved for different lymphomas, marking a significant advancement in the field...
February 18, 2024: Cancers
https://read.qxmd.com/read/38397899/unraveling-the-potential-of-alk-targeted-therapies-in-non-small-cell-lung-cancer-comprehensive-insights-and-future-directions
#15
REVIEW
Hannaneh Parvaresh, Ghazaal Roozitalab, Fatemeh Golandam, Payam Behzadi, Parham Jabbarzadeh Kaboli
Background and Objective: This review comprehensively explores the intricate landscape of anaplastic lymphoma kinase (ALK), focusing specifically on its pivotal role in non-small cell lung cancer (NSCLC). Tracing ALK's discovery, from its fusion with nucleolar phosphoprotein (NPM)-1 in anaplastic large cell non-Hodgkin's lymphoma (ALCL) in 1994, the review elucidates the subsequent impact of ALK gene alterations in various malignancies, including inflammatory myofibroblastoma and NSCLC. Approximately 3-5% of NSCLC patients exhibit complex ALK rearrangements, leading to the approval of six ALK-tyrosine kinase inhibitors (TKIs) by 2022, revolutionizing the treatment landscape for advanced metastatic ALK + NSCLC...
January 27, 2024: Biomedicines
https://read.qxmd.com/read/38362778/the-role-of-chimeric-antigen-receptor-t-cells-targeting-more-than-one-antigen-in-the-treatment-of-b-cell-malignancies
#16
REVIEW
Helena Brillembourg, Núria Martínez-Cibrián, Mireia Bachiller, Leticia Alserawan, Valentín Ortiz-Maldonado, Sònia Guedan, Julio Delgado
Several products containing chimeric antigen receptor T cells targeting CD19 (CART19) have been approved for the treatment of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukaemia (ALL). Despite very impressive response rates, a significant percentage of patients experience disease relapse and die of progressive disease. A major cause of CART19 failure is loss or downregulation of CD19 expression in tumour cells, which has prompted a myriad of novel strategies aimed at targeting more than one antigen (e...
February 16, 2024: British Journal of Haematology
https://read.qxmd.com/read/38339297/cancer-and-hiv-the-molecular-mechanisms-of-the-deadly-duo
#17
REVIEW
Aadilah Omar, Natasia Marques, Nicole Crawford
The immune deficiency associated with human immunodeficiency virus (HIV) infection causes a distinct increased risk of developing certain cancer types. Kaposi sarcoma (KS), invasive cervical cancer and non-Hodgkin's lymphoma (NHL) are the prominent malignancies that manifest as a result of opportunistic viral infections in patients with advanced HIV infection. Despite the implementation of antiretroviral therapy (ART), the prevalence of these acquired immunodeficiency syndrome (AIDS)-defining malignancies (ADMs) remains high in developing countries...
January 26, 2024: Cancers
https://read.qxmd.com/read/38321580/childhood-onset-systemic-lupus-erythematosus-csle-and-malignancy-a-nationwide-multicentre-series-review
#18
MULTICENTER STUDY
Matheus Zanata Brufatto, Sean Hideo Shirata Lanças, Taciana de Albuquerque Pedrosa Fernandes, Adriana Maluf Elias Sallum, Lucia Maria Arruda Campos, Ana Paula Sakamoto, Maria Teresa Terreri, Flavio Roberto Sztajnbok, Blanca Elena Rios Gomes Bica, Virginia Paes Leme Ferriani, Luciana Martins de Carvalho, Clovis Artur Almeida Silva, Claudia Saad-Magalhaes
BACKGROUND: Increased malignancy frequency is well documented in adult-systemic lupus erythematosus (SLE), but with limited reports in childhood-onset SLE (cSLE) series. We explored the frequency of malignancy associated with cSLE, describing clinical and demographic characteristics, disease activity and cumulative damage, by the time of malignancy diagnosis. METHOD: A retrospective case-notes review, in a nationwide cohort from 27 Pediatric Rheumatology centres, with descriptive biopsy-proven malignancy, disease activity/damage accrual, and immunosuppressive treatment were compiled in each participating centre, using a standard protocol...
February 6, 2024: Advances in Rheumatology
https://read.qxmd.com/read/38301513/prediction-model-of-radiotherapy-outcome-for-ocular-adnexal-lymphoma-using-informative-features-selected-by-chemometric-algorithms
#19
JOURNAL ARTICLE
Min Zhou, Jiaqi Wang, Jiahao Shi, Guangtao Zhai, Xiaowen Zhou, Lulu Ye, Lunhao Li, Menghan Hu, Yixiong Zhou
BACKGROUND: Ocular Adnexal Lymphoma (OAL) is a non-Hodgkin's lymphoma that most often appears in the tissues near the eye, and radiotherapy is the currently preferred treatment. There has been a controversy regarding the prognostic factors for systemic failure of OAL radiotherapy, the thorough evaluation prior to receiving radiotherapy is highly recommended to better the patient's prognosis and minimize the likelihood of any adverse effects. PURPOSE: To investigate the risk factors that contribute to incomplete remission in OAL radiotherapy and to establish a hybrid model for predicting the radiotherapy outcomes in OAL patients...
January 30, 2024: Computers in Biology and Medicine
https://read.qxmd.com/read/38296812/drug-loaded-biomimetic-carriers-for-non-hodgkin-s-lymphoma-therapy-advances-and-perspective
#20
REVIEW
Xiaoqi Li, Yu Zhang, Chao Wang, Liyuan Wang, Yufu Ye, Renyu Xue, Yuanwei Shi, Quanping Su, Yanxi Zhu, Lijuan Wang
Chemotherapy remains the mainstay of treatment for the lymphoma patient population, despite its relatively poor therapeutic results, high toxicity, and low specificity. With the advancement of biotechnology, the significance of drug-loading biomimetic materials in the medical field has become increasingly evident, attracting extensive attention from the scientific community and the pharmaceutical industry. Given that they can cater to the particular requirements of lymphoma patients, drug-loading biomimetic materials have recently become a potent and promising delivery approach for various applications...
January 31, 2024: ACS Biomaterials Science & Engineering
keyword
keyword
19119
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.